After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent rights to Sovaldi hepatitis C treatment. More than a victory for Gilead, it was the prevalence of fairness after years of underestimating the power to fairness to keep resurfacing until reinstated.
The Indian Patent Office had rejected Gilead’s patent application based on a notion that it did not demonstrate that the drug brings a significant improvement over another product produced by another firm. The office action was taken following challenging claims made by patients’ advocacy groups and drug makers.
The Indian . . .